scholarly journals Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I‑II and operable stage III breast cancer

2017 ◽  
Author(s):  
Xiying Shao ◽  
Lei Luo ◽  
Yong Guo ◽  
Xiaohong Xu ◽  
Dehou Deng ◽  
...  
2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e22088-e22088
Author(s):  
Xiying Shao ◽  
Yabing Zheng ◽  
Lei Shi ◽  
Yuan Huang ◽  
Yuheng Ding ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0121535 ◽  
Author(s):  
Xiying Shao ◽  
Yong Guo ◽  
Xiaohong Xu ◽  
Yabing Zheng ◽  
Jiwen Wang ◽  
...  

2020 ◽  
Vol 15 ◽  
Author(s):  
Athira K ◽  
Vrinda C ◽  
Sunil Kumar P V ◽  
Gopakumar G

Background: Breast cancer is the most common cancer in women across the world, with high incidence and mortality rates. Being a heterogeneous disease, gene expression profiling based analysis plays a significant role in understanding breast cancer. Since expression patterns of patients belonging to the same stage of breast cancer vary considerably, an integrated stage-wise analysis involving multiple samples is expected to give more comprehensive results and understanding of breast cancer. Objective: The objective of this study is to detect functionally significant modules from gene co-expression network of cancerous tissues and to extract prognostic genes related to multiple stages of breast cancer. Methods: To achieve this, a multiplex framework is modelled to map the multiple stages of breast cancer, which is followed by a modularity optimization method to identify functional modules from it. These functional modules are found to enrich many Gene Ontology terms significantly that are associated with cancer. Result and Discussion: predictive biomarkers are identified based on differential expression analysis of multiple stages of breast cancer. Conclusion: Our analysis identified 13 stage-I specific genes, 12 stage-II specific genes, and 42 stage-III specific genes that are significantly regulated and could be promising targets of breast cancer therapy. That apart, we could identify 29, 18 and 26 lncRNAs specific to stage I, stage II and stage III respectively.


1982 ◽  
Vol 18 (12) ◽  
pp. 1315-1320 ◽  
Author(s):  
John F. Stewart ◽  
Roger J.B. King ◽  
Peter J. Winter ◽  
David Tong ◽  
John L. Hayward ◽  
...  

2021 ◽  
Author(s):  
Bronte Morse ◽  
Kobi Decker

We have compared the global profiles of 100 tumors in Stage I, II and III with two independently releasedmicroarray datasets in order to understand their transcriptional behaviors accompanying a progression in breastcancer (1, 2). The olfactive receptor, family 56, subfamily A, member 4 OR56A4, was discovered to have beenone of the genes with the most varied expression when comparing initial tumors in stage I, stage II, and stageIII of breast cancer patients. In the stage III tumors, OR56A4 expression in comparison to the stage I tumorswas lower.


Cancer ◽  
2006 ◽  
Vol 106 (12) ◽  
pp. 2569-2575 ◽  
Author(s):  
Uwe Güth ◽  
Gad Singer ◽  
Igor Langer ◽  
Andreas Schötzau ◽  
Linda Herberich ◽  
...  

2021 ◽  
Vol 41 (7) ◽  
pp. 3625-3634
Author(s):  
KOSHO YAMANOUCHI ◽  
SHIGETO MAEDA ◽  
DAIKI TAKEI ◽  
YOICHI KOGA ◽  
MANPEI YAMASHITA ◽  
...  

1985 ◽  
Vol 71 (4) ◽  
pp. 339-344 ◽  
Author(s):  
Stefano Ciatto ◽  
Paolo Pacini ◽  
Patrizia Bravetti ◽  
Luigi Cataliotti ◽  
Gaetano Cardona ◽  
...  

The authors report on 1,017 consecutive breast cancer cases without symptomatic metastases staged by means of chest X-ray (CXR), skeletal survey (BXR) and bone scintigraphy (BS). Occult metastases (DM) detection rate was 0.88 %: 0.29 % for lung and 0.59 % for bone DM. The detection rate was correlated with clinical stage: 0.36 % for stage I, 0.20 % for stage II, 0.26 % for stages I and II, and 2.77 % for stage III cases. The sensitivity based on DM cases prevalent or surfacing within 6 months of follow-up was 0.30 for CXR, 0.22 for BXR and 0.55 for BS; specificity was 0.99, 0.98 and 0.90, respectively. The study confirms the possibility of early detection of DM with preoperative staging, but the extremely low detection rates in stage I and II cancers do not advise such a routine procedure. The higher detection rate of DM may suggest adoption of the routine staging procedure in stage III cancers. In these cases, although no evidence is available of a favorable prognostic impact of early detection and treatment of DM, an unnecessary mastectomy could be avoided in about 3 % of cases in the presence of DM detected by the staging procedure.


Sign in / Sign up

Export Citation Format

Share Document